Rafael Holdings Inc(RFL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.68 | Insider Own | 32.6% | Shs Outstand | 51.2M | Perf Week | -3.88% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 35.0M | Perf Month | -38.61% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | - | Inst Own | 7.51% | Short Float | 0.99% | Perf Quarter | -37.69% |
| Income | -0.03B | P/S | 65.81 | EPS this Y | - | Inst Trans | 4.8% | Short Ratio | 2.41 | Perf Half Y | -3.88% |
| Sales | 0.00B | P/B | 0.86 | EPS next 5Y | - | ROA | -32.54% | Short Interest | 0.35M | Perf YTD | 5.08% |
| Book/sh | 1.45 | P/C | 2.11 | EPS past 3/5Y | 44.95% -9.76% | ROE | -41.74% | 52W High | -68.69% ($3.96) | Perf Year | -8.15% |
| Cash/sh | 0.59 | P/FCF | - | Sales past 3/5Y | 30.78% -28.51% | ROIC | -43.18% | 52W Low | 10.71% ($1.12) | Perf 3Y | -19.53% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 26.75% | Gross Margin | 74.39% | Volatility(W/M) | 9.03% 9.25% | Perf 5Y | -95.87% |
| Dividend TTM | - | EV/Sales | 40.84 | Sales Y/Y TTM | 33.88% | Oper. Margin | -3717.24% | ATR (14) | 0.14 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.14 | EPS Q/Q | 55.81% | Profit Margin | -3321.73% | RSI (14) | 33.21 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.16 | Sales Q/Q | -50.55% | SMA20 | -11.65% ($1.4) | Beta | 0.74 | Target Price | - |
| Payout | - | Debt/Eq | 0.01 | Earnings | - | SMA50 | -33.85% ($1.87) | Rel Volume | 0.31 | Prev Close | $1.18 |
| Employees | 23 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -26.3% ($1.68) | Avg Volume(3M) | 0.14M | Price | $1.24 |
| IPO | 2018/3/27 | Option/Short | Yes/Yes | Trades | 168 | Volume | 45,489 | Change | 5.08% |
Raphael Holdings is a diversified holding company established in 2017 and headquartered in New Jersey, USA. The company simultaneously holds commercial real estate assets and invests in equity stakes in clinical-stage pharmaceutical companies, and is organized into three business segments: Healthcare, Infusion Technology, and Real Estate. It is a micro-cap holding company that combines the stable cash flow from real estate rental income with the growth potential of rare disease and oncology drug candidates.
Over the past 1 year, on the lower side
69% below its 1-year high.
Traded less than usual. That is 31% of its average volume.
RFL has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $6,581. Peers typically go for $133.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -95.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 7.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #29 of 45 in the industry
Based on market cap of $64M.
FAQ
What kind of company is RFL?
RFL belongs to the Real Estate sector and operates in the Real Estate Services industry.
What is the market cap of RFL?
The market cap of RFL is approximately $64M, ranking 4,714 within its sector.
What is the 52-week high and low for RFL?
RFL has recorded a 52-week high of $3.96 and a low of $1.12.
